Patient Test Result Report

Patient Name: Doe, Jane **DOB:** 01/01/1980 **Sex**: Female	**Collection Date:** 15Dec2020 **Processing Date**: 15Dec2020 **Location**: GoLab Mobile Lab #1	**Specimen Type:** Nasal Swab (1) **Test Type:** SARS-CoV-2 Rapid Antigen Test by BD Veritor (2)

TEST	RESULT	INTERPRETATION
SARS-CoV-2, Antigen Test	**NOT DETECTED***	SARS-CoV-2 was not detected in your sample**

* SARS-Cov-2 is considered a notifiable condition under Washington Administrative Code (WAC) 246-101, Notifiable Conditions. Results for COVID-19 testing will be reported to the Washington State Department of Health as required by law.
** Refer to the attached FDA Fact Sheet included with this report for more information regarding testing, intended use and interpretation of results. For further questions regarding this result, consultation with your primary care physician is recommended.

(1) An anterior nares or mid-turbinate specimen collected by a healthcare professional or self-collected by the patient is acceptable when the patient is in an appropriate clinical setting or under appropriate observation.
(2) This test is not yet approved or cleared by the United States FDA. When there are no FDA-approved or cleared tests available, and other criteria are met, FDA can make tests available under an emergency access mechanism called an Emergency Use Authorization (EUA), for use in authorized laboratories. The EUA for this test is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19. This EUA will remain in effect for the duration of the COVID-19 declaration justifying emergency of IVDs, under Section 564(b)(1) of the Act 21, U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.